Mobile App for Smoking Cessation in HIV
What You Need to Know Before You Apply
What is the purpose of this trial?
The present investigation aims to address disparities in cigarette use outcomes among Black/African American adults with HIV. The specific aims of this study are: (1) To modify a recently developed, culturally adapted, mobile application for Black smokers by integrating information specifically relevant to Black persons with HIV/AIDS. (2) To conduct a randomized clinical trial for anxiety-sensitivity reduction and cigarette cessation among Black smokers with HIV.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be receiving treatment for smoking cessation or substance use from outside the study.
Is the mobile app for smoking cessation safe for people with HIV?
The studies reviewed do not provide specific safety data for the mobile app itself, but they do suggest that smoking cessation interventions, including those using cell phone technology, are generally safe and can lead to health improvements like reduced blood pressure and increased immune function in people living with HIV.12345
How is the MASP+ treatment for smoking cessation in HIV unique?
MASP+ is unique because it leverages a mobile app to deliver smoking cessation support, which can increase accessibility and engagement for people living with HIV, a group with high smoking rates. This approach is novel compared to traditional methods, as it offers a potentially more sustainable and cost-effective way to reach and support this population.25678
What data supports the effectiveness of this treatment for smoking cessation in HIV?
Research shows that smoking cessation interventions using cell phone technology have been effective for people living with HIV, with some studies reporting high success rates. Additionally, combining nicotine replacement therapy with intensive counseling delivered via cell phone has shown promising results in helping HIV-positive individuals quit smoking.23569
Who Is on the Research Team?
Lorra Garey, Ph.D.
Principal Investigator
University of Houston
Michael Businelle, Ph.D.
Principal Investigator
University of Oklahoma
Are You a Good Fit for This Trial?
This trial is for Black/African American adults with HIV who smoke daily, want to quit smoking, and have moderate to high anxiety sensitivity. Participants must be over 18, motivated to quit (≥5 on a scale of 10), able to read English, and willing to use nicotine replacement therapy. Pregnant individuals or those planning pregnancy soon, non-English fluent speakers, people undergoing other treatments for smoking cessation or mental health issues are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the MASP+ app and receive nicotine replacement therapy to assist with smoking cessation
Follow-up
Participants are monitored for smoking abstinence and quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Control
- MASP+
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Houston
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
Baylor College of Medicine
Collaborator
University of Oklahoma
Collaborator